Register today for the 17th Annual Ruesch Center Symposium Scientific Day — Friday, November 20th, 2026! Join us for discussion, networking, and debate on critical issues related to GI cancers. @marshalj23 @LombardiCancer @MedStarHealth piped.video/fHIxh53s9Jw

Precision medicine is helping reshape how treatment decisions are made, but progress doesn’t always follow a straight line. In Oncology Unscripted by Decera Clinical Insights, @marshalj23, reflects on recent research showing improved outcomes with precision medicine approaches, while also considering studies that have challenged expectations and reinforced the need for continued investigation. From AI to precision medicine, new data are helping point the way forward while reminding us that evolving evidence can change how clinicians consider standard of care and how education can help clinicians determine how to bring the latest scientific advances into clinical action. . Watch the latest episode for Dr Marshall’s perspective on what these findings could mean for the future of oncology: bit.ly/4kcAhlI #Oncology #PrecisionMedicine #ArtificialIntelligence #CancerResearch #CancerCare #ScientificActivation #EvidenceToAction #Decode

Join @MedStarHealth for the Gastric and Soft Tissue Neoplasms Conference on November 7th. Attendees will gain insights into state-of-the-art care of gastric cancer, gastrointestinal stromal tumors, and retroperitoneal sarcomas while focusing on the importance of a multidisciplinary approach to the diagnosis and treatment of these complex disease entities. Register today using promo code GSTNMSH26: medstar.cloud-cme.com/course… nitter.siddz.com/RueschCenter/status/21…

Please join the Ruesch Center in congratulating Louis Weiner, MD, on being named a 2026 Luminary Award in GI Cancers recipient. This award honors individuals who have made transformative strides in the lives of patients with GI Cancers. Learn more: bit.ly/Luminary26. @LombardiCancer @MedStarGUH

The FDA has approved dostarlimab (Jemperli) for some adults with stage II or III rectal cancer whose tumors test MSI-H or dMMR. In the AZUR-1 trial, about 2 in 3 patients had a complete response lasting at least a year without surgery, based on their doctors’ assessments. The trial is ongoing and did not compare dostarlimab with standard treatment. Biomarker testing is the only way to know if a tumor has these markers. Ask your care team whether your tumor was tested and what your results mean for your treatment options. Read more on our blog 👉 crcancer.org/blog-dostarlima…

Living with or caring for someone with GI cancer? You’re not alone. Join @RueschCenter Nov 21 for Patient & Caregiver Day: survivorship, palliative care, and community. Register: hubs.li/Q04BxQrf0 @LombardiCancer @MedStarGUH @Onclive #GICancer #CaregiverSupport

Looking forward to an informative session with Zhifei Sun, MD, of @MedStarGUH at this year's Ruesch Center Symposium on Nov 21st. Register today using promo code Guest26: bit.ly/Ruesch26. @LombardiCancer

Under a month out: the Ruesch Center Patient & Caregiver Symposium is Nov 21. Breakout sessions on survivorship, palliative care, and caregiver support, plus community building all day. Register: hubs.li/Q04BjyMN0 @LombardiCancer @MedStarGUH @RueschCenter #GICancer #CaregiverSupport

Come check out my poster (@benweinbergmd) at noon CET in hall 5 on the CLOVER ☘️ study: leronlimab, anti-CCR5 weekly SC mAb $CYDY, given with Lonsurf/BEV in 3rd line+ mCRC - randomized phase II evaluating 350 vs 700 mg, well tolerated with no leronlimab-related DLTs, RAPID ctDNA reductions in most evaluable patients, early ORR by BICR 6.3% despite almost all with prior BEV, 100% CCR5 tissue expression! Study is ongoing #ESMO26 @myesmo

Hi! I’m Ben Weinberg, GI med onc from @RueschCenter @LombardiCancer @Georgetown taking over the @OncLive feed today at #ESMO26 covering all things GI cancer - follow along! @benweinbergmd

Please join us in congratulating Elizabeth Jaffee. M.D., FAACR, FACP, FAAAS, FAIO of @hopkinskimmel on being named a 2026 Luminary Award in GI Cancers recipient. This award honors individuals who have made transformative strides in the lives of patients with GI Cancers. Learn more: bit.ly/Luminary26.

We are thrilled to be joined by Julia Rowland, PhD, FAPOS, FASCO of @SmithCenterDC and @LombardiCancer to discuss "Finding and Utilizing Your Community Throughout the Cancer Care Continuum" at this year's Ruesch Center Symposium on Nov 21st. Register today using promo code Guest26: bit.ly/Ruesch26.

Please join us in congratulating @LynnMatrisian, Ph.D., MBA, FAACR, FAAAS of @PanCAN, on being named a 2026 Luminary Award in GI Cancers recipient. This award honors individuals who have made transformative strides in the lives of patients with GI Cancers. Learn more: bit.ly/Luminary26.

Join @MedStarHealth for the Gastric and Soft Tissue Neoplasms Conference on November 7th. Attendees will gain insights into state-of-the-art care of gastric cancer, gastrointestinal stromal tumors, and retroperitoneal sarcomas while focusing on the importance of a multidisciplinary approach to the diagnosis and treatment of these complex disease entities. Register today using promo code GSTNMSH26: medstar.cloud-cme.com/course…

We are excited to welcome Abigail Sweeney, JD, from @GeorgetownLaw's Health Justice Alliance to discuss "Navigating the Workplace, Financial Security, and Legal Concerns During Cancer Care" at this year's Ruesch Center Symposium on Saturday, November 21. Register today using the promo code Guest26 at bit.ly/Ruesch26.

We join our GI colleagues around the world in mourning the loss of Rachna Shroff, MD, MS, FASCO. Our thoughts are with her family, friends, mentees, research associates, advocacy groups she championed, and the @UAZCancer. nbcnews.com/health/disease/r…

In a new Georgetown University feature, Dr. John Marshall, the Alliance’s chief medical consultant, reflects on the rise of young-onset colorectal cancer and the urgent need to better understand its causes, accelerate clinical trials, and develop more precise treatments. Through initiatives like KLEOS, Dr. Marshall and the Alliance are working to move promising treatments forward faster, because patients cannot afford to wait. @marshalj23 Read more 👉 bit.ly/Georgetown-KLEOS